Information for patients. Treatment of HER2 positive early breast cancer.
D000293:Adolescent; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000175:diagnosis / Q000188:drug therapy* / Q000532:radiotherapy; D059248:Chemoradiotherapy; D003371:Cough / Q000139:chemically induced; D016903:Drug Monitoring / Q000379:methods; D004417:Dyspnea / Q000139:chemically induced; D055088:Early Detection of Cancer; D004487:Edema / Q000139:chemically induced; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D000068878:Trastuzumab; D016896:Treatment Outcome; D015430:Weight Gain / Q000187:drug effects; D055815:Young Adult
D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab